MCID: TYP007
MIFTS: 63

Typhoid Fever

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Typhoid Fever

MalaCards integrated aliases for Typhoid Fever:

Name: Typhoid Fever 12 52 58 54 3 43 15 17 71 32
Typhoid 12 74 52 58 15
Typhoidal Salmonellosis 58
Enteric Fever 52

Characteristics:

Orphanet epidemiological data:

58
typhoid
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),>1/1000 (South East Asia),1-5/10000 (Latin America),1-5/10000 (Africa),1-9/1000000 (North America),1-5/10000 (Oceania),1-9/1000000 (France); Age of onset: All ages; Age of death: adolescent,late childhood;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Typhoid Fever

Disease Ontology : 12 A primary bacterial infectious disease that is a communicable systemic illness, has material basis in Salmonella enterica subsp enterica serovar Typhi, which is transmitted by ingestion of food or water contaminated with the feces of an infected person. The infection has symptom fever, has symptom diarrhea, has symptom prostration, has symptom headache, has symptom splenomegaly, has symptom liver enlargement, has symptom eruption of rose-colored spots, and has symptom leukopenia.

MalaCards based summary : Typhoid Fever, also known as typhoid, is related to dengue disease and paratyphoid fever, and has symptoms including splenomegaly, fever and headache. An important gene associated with Typhoid Fever is SLC11A1 (Solute Carrier Family 11 Member 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Cefixime and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and bone, and related phenotypes are fatigue and fever

CDC : 3 Typhoid fever and paratyphoid fever are life-threatening illnesses caused by Salmonella serotype Typhi and Salmonella serotype Paratyphi, respectively. Most people in the United States with typhoid fever or paratyphoid fever become infected while traveling abroad, most often to countries where these diseases are common. If you plan to travel outside of the United States, find out if you need the typhoid fever vaccine at www.cdc.gov/travel.

Wikipedia : 74 Typhoid fever, also known simply as typhoid, is a bacterial infection due to a specific type of... more...

Related Diseases for Typhoid Fever

Diseases related to Typhoid Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 944)
# Related Disease Score Top Affiliating Genes
1 dengue disease 33.2 TNF GPT ALB
2 paratyphoid fever 32.7 TNF SLC11A1 IL1R1 IL1B IFNGR1 IFNG
3 salmonellosis 32.2 TNF TLR5 TLR4 SLC11A1 IL6 IL1B
4 intestinal perforation 31.8 IL6 GPT CRP ALB
5 epidemic typhus 31.6 TLR4 GPT CRP
6 cholecystitis 31.6 TLR4 GPT F2 ALB
7 guillain-barre syndrome 31.3 TNF HLA-DRB1 ALB
8 acute kidney failure 31.3 GPT F2 ALB
9 acalculous cholecystitis 31.3 GPT F2 CRP ALB
10 dysentery 31.2 TNF TLR4 IL6 IL1B CRP ALB
11 hepatitis 31.2 TNF IFNG GPT GGT1 F2
12 smallpox 31.2 TNF IL1B IFNG
13 myocarditis 31.2 TNF TLR4 IL6 IL1B IFNG ALB
14 splenic abscess 31.2 GPT F2 CRP ALB
15 disseminated intravascular coagulation 31.2 TNF IL6 GPT F2 CRP
16 yellow fever 31.1 IL6 IL1B CRP
17 tetanus 31.1 TNF IL6 IL1B IFNG CRP ALB
18 ascaris lumbricoides infection 31.1 IL6 IL1B IFNG
19 diarrhea 31.1 TNF TLR4 IL6 IL1B IFNG GPT
20 pancreatitis 31.0 TNF IL6 GGT1 CRP CFTR
21 brucellosis 31.0 TNF TLR4 SLC11A1 IL6 IFNG CRP
22 scarlet fever 31.0 TNF CRP ALB
23 spotted fever 31.0 TNF IFNG F2
24 hepatitis a 31.0 TNF TLR4 IFNG GPT GGT1 F2
25 purpura 31.0 TNF IL6 F2 CRP
26 optic neuritis 31.0 TNF IL1B HLA-DRB1
27 hepatic coma 31.0 GPT F2 ALB
28 gastroenteritis 31.0 TNF IL6 IL1B IFNG CRP ALB
29 neuritis 31.0 TNF IL6 IL1B IFNG
30 intussusception 31.0 IL6 CRP CFTR ALB
31 legionnaire disease 30.9 TLR5 CRP CASP1
32 orchitis 30.9 TNF IL6 CRP
33 gastritis 30.9 TNF TLR4 IL6 IL1B
34 toxic megacolon 30.9 TNF CRP ALB
35 syphilis 30.9 HLA-DRB1 GPT CRP ALB
36 amebiasis 30.9 TNF TLR4 ALB
37 exanthem 30.9 TNF IL6 GPT F2 CRP ALB
38 aortitis 30.9 TNF IL6 CRP
39 tularemia 30.8 TNF TLR4 SLC11A1 IL6 CASP1
40 intestinal obstruction 30.8 IL6 GPT CRP CFTR ALB
41 acute liver failure 30.8 GPT F2 ALB
42 pertussis 30.8 TNF TLR4 IL6 IL1B
43 uveitis 30.8 TNF IL6 IL1R1 IFNG
44 spondylitis 30.8 TNF IL6 IFNG CRP
45 ileitis 30.8 TNF TLR5 TLR4 IL6
46 meningitis 30.8 TNF TLR4 IL6 IL1B IFNG CRP
47 thrombophlebitis 30.8 F2 CRP ALB
48 appendicitis 30.7 TNF TLR4 IL6 IL1B IFNG CRP
49 iritis 30.7 TNF IL6 CRP
50 acute kidney tubular necrosis 30.7 IL6 GGT1 ALB

Graphical network of the top 20 diseases related to Typhoid Fever:



Diseases related to Typhoid Fever

Symptoms & Phenotypes for Typhoid Fever

Human phenotypes related to Typhoid Fever:

58 31 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
4 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
5 insomnia 58 31 hallmark (90%) Very frequent (99-80%) HP:0100785
6 hyperreflexia 58 31 frequent (33%) Frequent (79-30%) HP:0001347
7 ataxia 58 31 frequent (33%) Frequent (79-30%) HP:0001251
8 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
9 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
10 hypertonia 58 31 frequent (33%) Frequent (79-30%) HP:0001276
11 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
12 skin rash 58 31 frequent (33%) Frequent (79-30%) HP:0000988
13 macule 58 31 frequent (33%) Frequent (79-30%) HP:0012733
14 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
15 tremor 58 31 occasional (7.5%) Occasional (29-5%) HP:0001337
16 constipation 58 31 occasional (7.5%) Occasional (29-5%) HP:0002019
17 encephalitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002383
18 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
19 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
20 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936
21 coma 58 31 occasional (7.5%) Occasional (29-5%) HP:0001259
22 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
23 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
24 lethargy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001254
25 cardiac arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0001695
26 interstitial pulmonary abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0006530
27 arrhythmia 58 Frequent (79-30%)

Symptoms:

12
  • splenomegaly
  • fever
  • headache
  • diarrhea
  • leukopenia
  • prostration
  • liver enlargement
  • eruption of rose-colored spots

MGI Mouse Phenotypes related to Typhoid Fever:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 CFTR F2 GGT1 IFNG IFNGR1 IL1R1
2 homeostasis/metabolism MP:0005376 10.38 ALB CASP1 CFTR CRP F2 GGT1
3 cardiovascular system MP:0005385 10.37 ALB CASP1 CRP F2 IFNG IFNGR1
4 cellular MP:0005384 10.33 ALB CASP1 GGT1 IFNG IFNGR1 IL1R1
5 immune system MP:0005387 10.33 ALB CASP1 CFTR CRP F2 GGT1
6 growth/size/body region MP:0005378 10.32 CFTR F2 GGT1 IFNG IL1B IL1R1
7 hematopoietic system MP:0005397 10.31 CASP1 CFTR F2 GGT1 IFNG IFNGR1
8 mortality/aging MP:0010768 10.3 ALB CASP1 CFTR F2 GGT1 IFNG
9 digestive/alimentary MP:0005381 10.28 ALB CASP1 CFTR F2 IFNG IFNGR1
10 endocrine/exocrine gland MP:0005379 10.22 ALB CASP1 CFTR GGT1 IFNG IFNGR1
11 integument MP:0010771 10.17 CASP1 F2 GGT1 IFNG IFNGR1 IL1B
12 liver/biliary system MP:0005370 10.06 ALB CFTR IFNG IFNGR1 IL1R1 IL6
13 nervous system MP:0003631 10.03 CASP1 F2 IFNG IFNGR1 IL1B IL1R1
14 neoplasm MP:0002006 10.02 ALB CASP1 IFNG IFNGR1 IL1B IL1R1
15 renal/urinary system MP:0005367 9.76 ALB CASP1 GGT1 IFNG IFNGR1 IL1R1
16 respiratory system MP:0005388 9.61 CFTR F2 IFNG IL1R1 IL6 OMP
17 skeleton MP:0005390 9.32 F2 GGT1 GPT IFNG IFNGR1 IL1B

Drugs & Therapeutics for Typhoid Fever

Drugs for Typhoid Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefixime Approved, Investigational Phase 4 79350-37-1 54362 5362065
2
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
3
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
4
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
5
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
6 Antitubercular Agents Phase 4
7 Topoisomerase Inhibitors Phase 4
8 Ophthalmic Solutions Phase 4
9 Micronutrients Phase 4
10 Nutrients Phase 4
11 Trace Elements Phase 4
12 Vitamins Phase 4
13 Antioxidants Phase 4
14 Protective Agents Phase 4
15
Azithromycin Approved Phase 3 83905-01-5 55185 447043
16
Sulfamethoxazole Approved Phase 3 723-46-6 5329
17
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
18
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
19 Vaccines Phase 3
20 Immunologic Factors Phase 3
21 Anti-Bacterial Agents Phase 3
22 Anti-Infective Agents Phase 3
23 Renal Agents Phase 3
24 Antimalarials Phase 3
25 Antiparasitic Agents Phase 3
26 Anti-Infective Agents, Urinary Phase 3
27 Antiprotozoal Agents Phase 3
28 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
29
Zinc Approved, Investigational Phase 1, Phase 2 7440-66-6 32051
30
Secnidazole Approved Phase 1, Phase 2 3366-95-8
31
Albendazole Approved, Vet_approved Phase 1, Phase 2 54965-21-8 2082
32
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
33
Zinc sulfate Approved, Investigational Phase 1, Phase 2 7733-02-0
34
Furosemide Approved, Vet_approved Phase 2 54-31-9 3440
35
Artemether Approved Phase 2 71963-77-4 119380 68911
36
Lumefantrine Approved Phase 2 82186-77-4 6437380
37
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
39 Kava Approved, Investigational, Nutraceutical Phase 2 9000-38-8
40 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
41 retinol Phase 2
42 Retinol palmitate Phase 2
43 Astringents Phase 1, Phase 2
44 Antimitotic Agents Phase 1, Phase 2
45 Dermatologic Agents Phase 1, Phase 2
46 Anthelmintics Phase 1, Phase 2
47 diuretics Phase 2
48 Lecithin Phase 1, Phase 2
49 Soy Bean Phase 1, Phase 2
50 Immunoglobulins Phase 2

Interventional clinical trials:

(show top 50) (show all 86)
# Name Status NCT ID Phase Drugs
1 Typhoid Fever: Combined vs. Single Antibiotic Therapy. A Prospective Randomized Controlled Study in Nepal. Unknown status NCT02224040 Phase 4 ceftriaxone;ceftriaxone and azithromycin;azithromycin;azithromycin and cefixime
2 Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines Against Non-typhoid Salmonellae Unknown status NCT02121145 Phase 4
3 Randomized, Open-label, Superiority Trial of the Effectiveness of Gatifloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Enteric Fever. Completed NCT01421693 Phase 4 Ceftriaxone;Gatifloxacin
4 Typhoid Vi Vaccine Effectiveness in a Population Older Than 5 Years of Age Living in an Endemic Area in Hechi, Guangxi, P.R. China: A Group-Randomized Controlled Demonstration Project Completed NCT00131833 Phase 4
5 Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam. An Evaluation of Feasibility, Public Acceptability, Effectiveness and Cost-Effectiveness in Students Completed NCT00131820 Phase 4
6 Randomized Controlled Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever in Eastern Kolkata, West Bengal, India Completed NCT00125008 Phase 4
7 Effectiveness of a Combined Vi Vaccination and Health Education Program on Reducing the Burden of Typhoid During Childhood: A Demonstration Project in Karachi Completed NCT00125047 Phase 4
8 Treatment of 21st Century Typhoid Fever in Children;Open Label Mono vs Combination Drug Therapy Recruiting NCT04154722 Phase 4 Meropenem Injection;Azithromycin Powder
9 CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults Recruiting NCT03970304 Phase 4 Vivotif Typhoid Oral Vaccine
10 CVD 38000: Immunity, Microbiome, Epigenetics, and a Systems Biology Approach to the Study of Responses to Vaccination With Typhoid and/or Cholera Recruiting NCT03705585 Phase 4 Vivotif Typhoid Oral Vaccine;Vaxchora
11 Collection of Blood Samples for In-Vitro Studies From Healthy Adult Blood Donors Who Have Received Oral Typhoid Vaccine (TY21A) Recruiting NCT03971669 Phase 4 Vivotif Typhoid Oral Vaccine
12 Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation Recruiting NCT03889158 Phase 4
13 Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction: A Prospective, Controlled Community Embedded Study With Vaccines With Low Coverage Rates (The Improve ACCESS Study) Active, not recruiting NCT02868970 Phase 4
14 Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort Active, not recruiting NCT03312699 Phase 4
15 Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects Completed NCT01608815 Phase 3
16 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
17 A Phase III, Open, Randomized, Multicentric Study to Compare the Reactogenicity and Immunogenicity of GSK Biologicals' Combined Vi Polysaccharide Typhoid Vaccine and Inactivated Hepatitis A Vaccine, to That Elicited by GSK Biologicals' Hepatitis A Vaccine, Administered Singly or Concomitantly With GSK Biologicals' Vi Polysaccharide Vaccine Completed NCT00197249 Phase 3
18 Improving the Immune Response to Rotavirus Vaccine Completed NCT01825109 Phase 3
19 A Phase III Randomized, Double-Blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Recruiting NCT03299426 Phase 3
20 A Phase III Multicenter, Observer-Blinded, Randomized, Active Controlled, Immune Non-inferiority and Safety Study of Vi-DT Vaccine Compared to Typbar TCV® in Healthy 6 Months-45 Years Aged Nepalese Participants. Recruiting NCT03933098 Phase 3
21 Parallel Group, Double Blinded, 1:1, Randomized Controlled Phase III Trial of Co-trimoxazole Versus Azithromycin for the Treatment of Undifferentiated Fever In Nepal Active, not recruiting NCT02773407 Phase 3 Azithromycin;Co-trimoxazole
22 Immunogenicity and Safety of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults, Children and Infants, Lot to Lot Consistency, Non-inferiority to PQed (Prequalified) TCV (Typhoid Conjugate Vaccine) Not yet recruiting NCT04051268 Phase 3
23 A Phase III, Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Immune Equivalence of Multi-dose Formulation Against Single-dose Formulation of Vi-DT Typhoid Conjugate Vaccine and Safety in Healthy Filipino...... Not yet recruiting NCT04204096 Phase 3
24 A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of a Single Oral Dose Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects Completed NCT00498654 Phase 2
25 A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants Completed NCT01437267 Phase 2
26 A Phase 2a, Randomized, Controlled, Observer Blind, Age De-Escalation, Multicenter and Multinational Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants Completed NCT01229176 Phase 2
27 A Phase 2, Open-label, Single-center, Extension Study to Evaluate the Booster Response Induced by Vi-CRM197 After Priming With Either Vi-CRM197 or Typherix Administered in Adult Subjects in H01_04TP Study (NCT01193907) Completed NCT01438996 Phase 2
28 A Phase 2, Randomized, Observer-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the Novartis Vaccines Institute for Global Health (NVGH) Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age Completed NCT01193907 Phase 2
29 A Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study to Determine the Immunogenicity, Safety and Tolerability of S. Typhi (Ty2 aroC‾ssaV‾) ZH9 at Doses of 5.0 x 10E9 CFU, 7.5 x 10E9 CFU, 1.1 x 10E10 and 1.7 x 10E10 CFU and 1.7 x 10E10 CFU, Following Oral Administration to Healthy, Typhoid Vaccine naïve Subjects in the USA. Completed NCT00679172 Phase 2
30 A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, In-Patient Phase I/II Study to Determine the Safety and Immunogenicity of Ty800 in Healthy Adult Subjects Completed NCT00269295 Phase 1, Phase 2 Placebo
31 Evaluation of the Safety, Immunogenicity and Compatibility With DTP of an Investigational Vi-rEPA Conjugate Vaccine for Typhoid Fever When Administered to Infants in Vietnam Concurrently With DTP Completed NCT00342628 Phase 2
32 Studies of Acute and Memory Immune Responses to Orally Administered Vaccines in Developing Country Children and Factors That May Augment Such Responses Completed NCT01019083 Phase 1, Phase 2 Placebo;Placebo;Zinc Sulphate;Albendazole and Secnidazole
33 MANAGEMENT OF THE PATIENT WITH ACUTE ABDOMEN SUBMITTED TO URGENT ABDOMINAL SURGERY: a Pilot Randomized Multicentre Study Completed NCT01911702 Phase 2
34 Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Prostate Carcinoma Patient Completed NCT02338700 Phase 1, Phase 2
35 Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Breast Carcinoma Patient Completed NCT02338804 Phase 1, Phase 2
36 Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Hepatocyte Carcinoma Patient Completed NCT02338778 Phase 1, Phase 2
37 Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Pancreatic Carcinoma Patient Completed NCT02338752 Phase 1, Phase 2
38 Safety, Immunogenicity and Efficacy of Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali Recruiting NCT03917654 Phase 2
39 A Phase IIb, Observer-blind, Randomised Controlled Trial to Assess the Immunogenicity and Protective Efficacy of Vi Conjugated (Vi-TCV) and Unconjugated (Vi-PS) Polysaccharide Vaccines in Preventing Typhoid Infection Compared to a Control Vaccine (Meningococcal ACWY), Using a Human Challenge Model of Typhoid Infection Active, not recruiting NCT02324751 Phase 2
40 Understanding Typhoid Disease After Vaccination: a Single Centre, Randomised, Doubleblind, Placebo Controlled Study to Evaluate M01ZH09 in a Healthy Adult Challenge Model, Using Ty21a Vaccine as a Positive Control. Active, not recruiting NCT01405521 Phase 2
41 Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Indonesian Adults, Adolescents, Children and Infants (Phase II) Active, not recruiting NCT03460405 Phase 2
42 A Phase II, Randomized, Dose-scheduling, Observer-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of Vi-DT Conjugate Vaccine in 6-23-Month Old Healthy Filipino Infants and Toddlers Active, not recruiting NCT03527355 Phase 2
43 A Phase 2 Randomized, Double-Blind, Controlled Trial of the Safety and Immunogenicity of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Active, not recruiting NCT03614533 Phase 2
44 An Open-label Bi-centric Study of Local Immunomodulation Treatment Combined With Radiofrequency Ablation for Unresectable Colorectal Liver Metastases Not yet recruiting NCT04062721 Phase 1, Phase 2 Chemotherapy;In situ immunotherapy
45 A Controlled Study of Salmonella Ty21a and Cholera/ ETEC-vaccine and the Role of Oats in Daily Diet as a New Treatment in Patients With Mild or Moderate Ulcerative Colitis. Terminated NCT00751933 Phase 2
46 A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age. Completed NCT01123941 Phase 1
47 Phase I Trial of a Live Oral Salmonella Enterica Serovar Paratyphi A Vaccine Harboring Mutations in guaBA and clpX Completed NCT01129453 Phase 1
48 An Open-label, Comparative, Clinical Phase 1 Study to Assess the Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults Completed NCT03956524 Phase 1
49 A Randomized, Observer Blinded, Comparative, Phase I Safety Study in Two Age De-escalating Cohorts to Assess the Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I) Completed NCT03109600 Phase 1
50 A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Trial to Determine the Safety and Immunogenicity of Typhax Delivered IM Completed NCT03926455 Phase 1

Search NIH Clinical Center for Typhoid Fever

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin

Cochrane evidence based reviews: typhoid fever

Genetic Tests for Typhoid Fever

Anatomical Context for Typhoid Fever

MalaCards organs/tissues related to Typhoid Fever:

40
Testes, Liver, Bone, Colon, T Cells, Heart, Skin

Publications for Typhoid Fever

Articles related to Typhoid Fever:

(show top 50) (show all 11669)
# Title Authors PMID Year
1
Polymorphisms in proinflammatory genes and susceptibility to typhoid fever and paratyphoid fever. 54 61
17477815 2007
2
Rapid diagnosis of typhoid fever by enzyme-linked immunosorbent assay detection of Salmonella serotype typhi antigens in urine. 54 61
15031525 2004
3
A Salmonella protein causes macrophage cell death by inducing autophagy. 54 61
14662750 2003
4
Typhoid fever and genetic polymorphisms at the natural resistance-associated macrophage protein 1. 54 61
11237848 2001
5
Rapid serologic diagnosis of pediatric typhoid fever in an endemic area: a prospective comparative evaluation of two dot-enzyme immunoassays and the Widal test. 54 61
10548305 1999
6
Diagnosis of typhoid fever: detection of Salmonella typhi porins-specific antibodies by inhibition ELISA. 54 61
8222322 1993
7
Detection of antibodies against Salmonella typhi outer membrane protein (OMP) preparation in typhoid fever patients. 54 61
8216558 1993
8
Early diagnosis of typhoid fever by an enzyme immunoassay using Salmonella typhi outer membrane protein preparations. 54 61
8513812 1993
9
Lipopolysaccharide-independent radioimmunoprecipitation and identification of structural and in vivo induced immunogenic surface proteins of Salmonella typhi in typhoid fever. 54 61
8427032 1993
10
Human cell mediated immunity to porins from Salmonella typhi. 54 61
8384733 1993
11
Spatial and spatiotemporal patterns of typhoid fever and investigation of their relationship with potential risk factors in Iran, 2012-2017. 61
31978729 2020
12
Galloyl flavonoids from Acacia farnesiana pods possess potent anthelmintic activity against Haemonchus contortus eggs and infective larvae. 61
31739102 2020
13
Outer membrane protein OmpV mediates Salmonella enterica serovar typhimurium adhesion to intestinal epithelial cells via fibronectin and α1β1 integrin. 61
32017350 2020
14
Using Clinical Profiles and Complete Blood Counts to Differentiate Causes of Acute Febrile Illness during the 2009-11 Outbreak of Typhoid and Chikungunya in a Dengue Endemic Area. 61
32016406 2020
15
Ethnomedicinal survey and mutagenic studies of plants used in Accra metropolis, Ghana. 61
31654798 2020
16
Causes of fever in Gabonese children: a cross-sectional hospital-based study. 61
32034188 2020
17
[Epidemiology profil of fever typhoid in Meknes (Morocco) 2013-2016]. 61
31917023 2020
18
Cost-effectiveness of using environmental surveillance to target the roll-out typhoid conjugate vaccine. 61
31917040 2020
19
A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever. 61
31905228 2020
20
Seroprevalence of chikungunya virus infection in five hospitals within anyigba, kogi State of Nigeria. 61
32001210 2020
21
Identification of chloramphenicol in human hair leading to a diagnosis of factitious disorder. 61
31913719 2020
22
High index of suspicion for brucellosis in a highly cosmopolitan city in southern China. 61
31914937 2020
23
[Travel vaccinations]. 61
31802155 2020
24
Comparison of antibiotic prescriptions in adults and children with upper respiratory tract infections in Bangka Tengah primary health care centers. 61
31926085 2020
25
Prevalence of Trachoma in Pakistan: Results of 42 Population-Based Prevalence Surveys from the Global Trachoma Mapping Project. 61
31916887 2020
26
Vaccination Programs for Adults in Europe, 2019. 61
31968652 2020
27
Spectroscopic characterisation of a series of Salmonella Typhi Vi-diphtheria toxoid glycoconjugate antigens differing in polysaccharide-protein ratio. 61
31991319 2020
28
Re-evaluating herd protection by Vi typhoid vaccine in a cluster randomized trial. 61
31608962 2020
29
Under-detection of blood culture-positive enteric fever cases: The impact of missing data and methods for adjusting incidence estimates. 61
31945052 2020
30
Chain effects of clean water: The Mills-Reincke phenomenon in early 20th-century Japan. 61
31655396 2020
31
Pakistan: country report on children's environmental health. 61
31926105 2020
32
Bacterial Genotoxin-Induced DNA Damage and Modulation of the Host Immune Microenvironment. 61
31973033 2020
33
Anti quorum sensing and anti virulence activity of tannic acid and it's potential to breach resistance in Salmonella enterica Typhi / Paratyphi A clinical isolates. 61
31654777 2020
34
Virulence traits and expression of bstA, fliC and sopE2 in Salmonella Dublin strains isolated from humans and animals in Brazil. 61
31931258 2020
35
Disease-specific out-of-pocket healthcare expenditure in urban Bangladesh: A Bayesian analysis. 61
31935266 2020
36
Phylogenetic Analysis Indicates a Longer Term Presence of the Globally Distributed H58 Haplotype of Salmonella Typhi in Southern India. 61
32003431 2020
37
One-month follow up of a randomized clinical trial-phase II study in 6-<24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine. 61
32004693 2020
38
Organic acids and 2,4-Di-tert-butylphenol: major compounds of Weissella confusa WM36 cell-free supernatant against growth, survival and virulence of Salmonella Typhi. 61
31998561 2020
39
Mechanisms of substrate recognition by a typhoid toxin secretion-associated muramidase. 61
31958059 2020
40
Drug-Resistant Salmonella typhi in Pakistan. 61
31603009 2020
41
Characterization and analytical validation of a new antigenic rapid diagnostic test for Ebola virus disease detection. 61
31951615 2020
42
Differential functional patterns of memory CD4+ and CD8+ T-cells from volunteers immunized with Ty21a typhoid vaccine observed using a recombinant Escherichia coli system expressing S. Typhi proteins. 61
31629569 2020
43
Distinct but Intertwined Evolutionary Histories of Multiple Salmonella enterica Subspecies. 61
31937675 2020
44
A conjugate vaccine for typhoid. 61
31932795 2020
45
Antiquorum sensing and antibiofilm potential of biosynthesized silver nanoparticles of Myristica fragrans seed extract against MDR Salmonella enterica serovar Typhi isolates from asymptomatic typhoid carriers and typhoid patients. 61
31836973 2020
46
Typhoid in Laos: An 18-Year Perspective. 61
31989918 2020
47
Travel-Related Typhoid Fever: Narrative Review of the Scientific Literature. 61
31963643 2020
48
Phylogenetic Analysis for the Origin of Typhoid Fever Outbreak on Jeju Island, Korea, in 2017. 61
31997603 2020
49
Burden of typhoid fever and cholera: similarities and differences. Prevention strategies for European travelers to endemic/epidemic areas. 61
31967084 2019
50
Burden of Typhoid Fever in the Rural Field Practice Area of a Medical College, Bengaluru, India - A Descriptive Study. 61
31801343 2019

Variations for Typhoid Fever

Expression for Typhoid Fever

Search GEO for disease gene expression data for Typhoid Fever.

Pathways for Typhoid Fever

Pathways related to Typhoid Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 TNF TLR5 TLR4 SLC11A1 IL6 IL1R1
2
Show member pathways
13.74 TNF TLR4 IL6 IL1R1 IL1B IFNGR1
3
Show member pathways
13.43 TNF IL6 IL1R1 IL1B IFNGR1 IFNG
4
Show member pathways
13.29 TNF TLR5 TLR4 IL1R1 IL1B IFNGR1
5
Show member pathways
13.21 TNF TLR5 TLR4 IL6 IL1B IFNGR1
6
Show member pathways
13 TNF TLR4 IL6 IL1R1 IL1B IFNGR1
7 12.88 TNF IL6 IL1B IFNGR1 IFNG HLA-DRB1
8
Show member pathways
12.85 TNF TLR4 IL6 IL1B IFNG CASP1
9
Show member pathways
12.85 VDAC1 TNF TLR4 IL6 IL1B IFNGR1
10
Show member pathways
12.79 TNF TLR5 TLR4 IL6 IL1R1 IL1B
11
Show member pathways
12.73 TNF IL1R1 IL1B IFNGR1 IFNG
12
Show member pathways
12.7 TNF TLR4 IL6 IL1B IFNGR1 IFNG
13
Show member pathways
12.68 TNF TLR5 TLR4 IL1R1 IL1B CASP1
14
Show member pathways
12.66 TNF IL6 IL1B IFNG F2
15
Show member pathways
12.51 TNF TLR5 TLR4 IL6 IL1R1 IL1B
16 12.46 VDAC1 VAC14 TNF IL6 IL1R1 HLA-DRB1
17 12.46 VDAC1 TNF TLR5 TLR4 IL1R1 IL1B
18
Show member pathways
12.44 TNF TLR5 IL6 IL1B IFNG CFTR
19
Show member pathways
12.42 TNF TLR4 IL6 IL1R1 IL1B IFNGR1
20
Show member pathways
12.37 TNF TLR4 IL1B IFNGR1 IFNG HLA-DRB1
21 12.35 VDAC1 TNF TLR4 IL6 IL1B CASP1
22
Show member pathways
12.32 TNF TLR5 TLR4 IL6
23
Show member pathways
12.32 TNF TLR5 IL6 IL1R1 IL1B CFTR
24
Show member pathways
12.3 TNF IL6 IL1B IFNG GGT1 F2
25
Show member pathways
12.28 TNF IL6 IL1B CASP1
26 12.28 TNF TLR5 TLR4 IL6 IFNGR1 IFNG
27 12.28 TNF TLR4 IL6 IL1B IFNGR1 IFNG
28
Show member pathways
12.24 VDAC1 TNF TLR4 IL1B IFNGR1 IFNG
29 12.17 TNF IL1R1 IL1B IFNG
30 12.17 TNF IL1R1 IL1B IFNGR1 IFNG
31 12.16 TNF TLR5 TLR4 IL6 IL1R1 IL1B
32
Show member pathways
12.14 TNF TLR4 IL6 IL1B IFNG F2
33 12.13 TNF TLR4 IL6 IL1B CASP1
34
Show member pathways
12.11 TLR5 TLR4 IL1R1 IL1B
35 12.09 TNF TLR4 IL6 IL1R1 IL1B IFNG
36
Show member pathways
12.07 IL1R1 IL1B IFNG HLA-DRB1
37 12.05 TLR4 IL6 IFNGR1 IFNG
38 12.03 TNF IL6 IL1R1 IL1B HLA-DRB1
39 12.01 TNF TLR4 IL1R1 IL1B
40 12.01 TNF TLR4 IL6 IL1R1 IL1B IFNG
41
Show member pathways
11.96 IL1B IFNGR1 IFNG CASP1
42 11.96 TNF TLR4 IL6 IL1B IFNG HLA-DRB1
43 11.89 TNF IL1R1 IL1B IFNG
44 11.87 TNF TLR4 IL6 IL1B CASP1
45 11.86 TNF IL6 IL1B IFNG
46 11.84 TNF IL6 IL1B IFNG
47
Show member pathways
11.78 TNF IL6 IL1B IFNG
48 11.72 TNF IL6 IL1B
49
Show member pathways
11.67 TNF TLR5 TLR4 IL6 IL1R1 IL1B
50 11.66 TNF IL6 IL1R1 IL1B

GO Terms for Typhoid Fever

Cellular components related to Typhoid Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TNF IL6 IL1B IFNG GPT GGT1
2 external side of plasma membrane GO:0009897 9.55 TNF TLR4 IL1R1 HLA-DRB1 F2
3 endosome membrane GO:0010008 9.02 VAC14 TLR4 SLC11A1 HLA-DRB1 CFTR

Biological processes related to Typhoid Fever according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 VAC14 TLR5 TLR4 OMP IL6 IL1R1
2 cytokine-mediated signaling pathway GO:0019221 10.01 TNF IL6 IL1R1 IL1B IFNGR1 CASP1
3 immune response GO:0006955 10.01 TNF TLR4 SLC11A1 IL6 IL1R1 IL1B
4 positive regulation of protein phosphorylation GO:0001934 9.98 TNF IL1B IFNG F2
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 TNF TLR4 IL1B CASP1
6 response to lipopolysaccharide GO:0032496 9.97 TLR4 SLC11A1 IL1B GGT1
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 TNF TLR4 IL6 IL1B
8 positive regulation of gene expression GO:0010628 9.92 TNF TLR4 SLC11A1 IL6 IL1B IFNGR1
9 cellular response to lipopolysaccharide GO:0071222 9.91 TNF TLR5 TLR4 IL6 IL1B CASP1
10 cellular response to mechanical stimulus GO:0071260 9.9 TLR5 TLR4 IL1B CASP1
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.87 TNF IL6 IFNG
12 interferon-gamma-mediated signaling pathway GO:0060333 9.87 IFNGR1 IFNG HLA-DRB1
13 regulation of insulin secretion GO:0050796 9.87 TNF IL1B IFNG
14 positive regulation of interleukin-6 production GO:0032755 9.87 TNF TLR4 IL6 IL1B
15 apoptotic signaling pathway GO:0097190 9.86 TNF TLR4 CASP1
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF TLR4 IL1B
17 humoral immune response GO:0006959 9.85 TNF IL6 IFNG
18 regulation of inflammatory response GO:0050727 9.85 TNF TLR4 IL1R1 GGT1 CASP1
19 acute-phase response GO:0006953 9.82 IL6 F2 CRP
20 positive regulation of interleukin-6 secretion GO:2000778 9.82 TNF TLR4 IL1B
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 TNF TLR4 IL1B
22 positive regulation of JAK-STAT cascade GO:0046427 9.81 TNF IL6 F2
23 positive regulation of phagocytosis GO:0050766 9.81 TNF SLC11A1 IL1B IFNG
24 microglial cell activation GO:0001774 9.8 TNF IFNGR1 IFNG
25 negative regulation of neurogenesis GO:0050768 9.8 TNF IL6 IL1B
26 positive regulation of chemokine production GO:0032722 9.78 TNF TLR4 IL6
27 positive regulation of interleukin-8 production GO:0032757 9.78 TNF TLR5 TLR4 IL1B
28 positive regulation of glial cell proliferation GO:0060252 9.77 TNF IL6 IL1B
29 positive regulation of amyloid-beta formation GO:1902004 9.76 TNF IFNGR1 IFNG
30 inflammatory response GO:0006954 9.76 TNF TLR5 TLR4 SLC11A1 IL6 IL1R1
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.75 TNF IL1B IFNG
32 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL6 IL1B
33 positive regulation of chemokine biosynthetic process GO:0045080 9.72 TNF IL1B IFNG
34 macrophage activation GO:0042116 9.7 TLR4 SLC11A1
35 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 TLR4 IFNG
36 T-helper 1 type immune response GO:0042088 9.7 TLR4 HLA-DRB1
37 negative regulation of amyloid-beta clearance GO:1900222 9.7 TNF IFNGR1 IFNG
38 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF IL1B
39 negative regulation of lipid storage GO:0010888 9.67 TNF IL6 CRP
40 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.66 IL1R1 IL1B
41 positive regulation of fever generation GO:0031622 9.66 TNF IL1B
42 sequestering of triglyceride GO:0030730 9.65 TNF IL1B
43 positive regulation of vitamin D biosynthetic process GO:0060557 9.62 TNF IFNG
44 positive regulation of nitrogen compound metabolic process GO:0051173 9.61 TNF IFNG
45 astrocyte activation GO:0048143 9.56 TNF IL1B IFNGR1 IFNG
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 TNF IL1B IFNG
47 positive regulation of nitric oxide biosynthetic process GO:0045429 9.35 TNF TLR5 TLR4 IL1B IFNG
48 positive regulation of interferon-gamma production GO:0032729 9.02 TNF TLR4 SLC11A1 IL1R1 IL1B

Molecular functions related to Typhoid Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IL6 IL1B IFNG

Sources for Typhoid Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....